New ALS drug PrimeC shows promise in Mid-Stage trial
NCT ID NCT05357950
First seen Oct 31, 2025 · Last updated May 25, 2026 · Updated 27 times
Summary
This study tested a new drug called PrimeC in 69 people with ALS (Lou Gehrig's disease) to see if it is safe and can slow the disease. Participants took PrimeC or a placebo twice daily for 6 months, and everyone who finished could then receive PrimeC for another 12 months. The goal was to measure side effects, survival, and changes in muscle function and breathing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
A.O.U. Citta della Salute e della Scienza di Torino
Torino, Italy
-
IRCCS Istituti clinici Maugeri
Milan, Italy
-
Lawson Health Research Institute
London, Ontario, Canada
-
Tel Aviv Sourasky Medical Center
Tel Aviv, Israel
Conditions
Explore the condition pages connected to this study.